NCT05451199

A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 154 (estimated)
• Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	ICP-488	ICP-488 will be administered as tablet
DRUG	Placebo	Matching placebo will be administered as tablet

Timeline

• Start date: 2022-07-29
• Primary completion: 2023-10-30
• Completion: 2023-12-31
• First posted: 2022-07-11
• Last updated: 2023-04-18

Locations

7 sites across 1 country: China